Asahi Glass Company (TYO: 5201), a global glass manufacturing firm known as AGC, has announced a new deal with a biopharmaceutical contract development and manufacturing organization (CDMO).
AGC is to acquire 100% of the shares in CMC Biologics, the active pharmaceutical ingredient (API) manufacturer with production facilities in Denmark and the USA and backed by investors including Monitor Clipper Partners and European Equity Partners, for around 60 billion Japanese yen ($510 million).
CMC provides high value-added cell line construction, process development, scale-up and manufacturing of APIs used in drug development and in commercially marketed biopharmaceutical drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze